Provisions A Synthetic Drug Awareness 7001. Short title This subtitle may be cited as the Synthetic Drug Awareness Act of 2018 . 7002. Report on effects on public health of synthetic drug use (a) In general Not later than 3 years after the date of the enactment of this Act, the Surgeon General of the Public Health Service shall submit to Congress a report on the health effects of new psychoactive substances (including synthetic drugs) used since January 2010 by persons who are at least 12 years of age but no more than 18 years of age. (b) New psychoactive substance defined For purposes of subsection (a), the term new psychoactive substance means a controlled substance analogue (as defined in section 102(32) of the Controlled Substances Act ( 21 U.S.C. 802(32) ). B Empowering Pharmacists in the Fight Against Opioid Abuse 7011. Short title This subtitle may be cited as the Empowering Pharmacists in the Fight Against Opioid Abuse Act . 7012. Programs and materials for training on certain circumstances under which a pharmacist may decline to fill a prescription (a) In general Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with the Administrator of the Drug Enforcement Administration, the Commissioner of Food and Drugs, the Director of the Centers for Disease Control and Prevention, and the Assistant Secretary for Mental Health and Substance Use, shall develop and disseminate programs and materials for training pharmacists, health care providers, and patients on— (1) circumstances under which a pharmacist may, consistent with section 201 of the Controlled Substances Act ( 21 U.S.C. 811 ) and regulations thereunder, including section 1306.04 of title 21, Code of Federal Regulations, decline to fill a prescription for a controlled substance because the pharmacist suspects the prescription is fraudulent, forged, or otherwise indicative of abuse or diversion